Senegal is one of West Africa's most politically stable democracies, with a GDP exceeding $32 billion and a population of approximately 18 million. Dakar, the capital, serves as a key Francophone Africa political hub and hosts the headquarters of numerous international organisations, NGOs, and development finance institutions. The country's market research environment is shaped by its strong public health infrastructure — including the Institut Pasteur de Dakar, a globally recognised research institution — alongside significant USAID, WHO, and GAVI programme presence.
The Senegalese pharmaceutical market is regulated by the DPM (Direction de la Pharmacie et du Médicament) under the Ministère de la Santé du Sénégal, with activity further shaped by UEMOA harmonised regulations and the CEDEAO (ECOWAS) trade framework. Senegal has a long tradition of public health research and clinical trial activity, making it a relatively data-rich environment by West African standards. Research buyers in the pharmaceutical and healthcare sector require partners with DPM regulatory awareness, UEMOA knowledge, and familiarity with the public health programme landscape that dominates healthcare delivery.
The transformative development of the Sangomar offshore oil field and associated gas projects is reshaping Senegal's economic trajectory, with the Plan Sénégal Émergent (PSE) and Teranga Plan providing a strategic development framework. New oil revenues are creating demand for market entry intelligence, infrastructure research, and consumer market studies in a rapidly evolving economy. Market research in Senegal is conducted in French as the primary business language, and Dakar's role as a Francophone Africa political capital makes it a natural hub for multi-country West Africa research programmes.